mg% [qnco]
17 beta-Estradiol [horm, phsu, strd]
Combined [qlco]
Sequential [idcn]
Dydrogesterone [horm, phsu, strd]
effects [qlco]
serum lipid [lbpr]
Profile [lbpr]
postmenopausal [tmco]
Women [popg]
objectives [inpr]
Study [mnob]
effects [qlco]
mg% [qnco]
17 beta-Estradiol [horm, phsu, strd]
serum lipid [lbpr]
Profile [lbpr]
effects [qlco]
Established [qlco]
Previous [tmco]
mg% [qnco]
Dose [qnco]
Required [ftcn]
effects [qlco]
mg% [qnco]
Dose [qnco]
Methods [inpr]
thi [euka]
Double-Blind Study [resa]
placebo-controlled [resa]
postmenopausal [tmco]
Women [popg]
randomized [resa]
Oral [spco]
treatment [ftcn]
placebo [topp]
1 Day [tmco]
mg% [qnco]
17 beta-Estradiol [horm, phsu, strd]
Combined [qlco]
mg day [qnco]
Dydrogesterone [horm, phsu, strd]
Last [qlco]
days [tmco]
Cycle [tmco]
mg day [qnco]
17 beta-Estradiol [horm, phsu, strd]
Combined [qlco]
mg day [qnco]
Dydrogesterone [horm, phsu, strd]
Last [qlco]
days [tmco]
Cycle [tmco]
treatment [ftcn]
Continued [idcn]
Cycle [tmco]
High density lipoprotein cholesterol level [lbpr]
P NOS [aapp, imft]
Increased [qnco]
Cycle [tmco]
Active Treatment [topp]
Group [idcn]
Compared [acty]
placebo [topp]
Addition [ftcn]
Low Density Lipoprotein Cholesterol [bacs, strd]
Lipoprotein (a) [aapp, bacs]
Reduced [qlco]
Apolipoprotein A-I [aapp, bacs]
Triglyceride level [lbtr]
Increased [qnco]
Active Treatment [topp]
Group [idcn]
Cycle [tmco]
Conclusions [idcn]
Study [mnob]
Sequential [idcn]
Combinations [mnob]
mg% [qnco]
17 beta-Estradiol [horm, phsu, strd]
Dydrogesterone [horm, phsu, strd]
Favorable [qlco]
serum lipid [lbpr]
Profile [lbpr]
Dydrogesterone [horm, phsu, strd]
compromise [fndg]
17 beta-Estradiol [horm, phsu, strd]
Induced [ftcn]
Improvement [cnce]
Lipid [lipd]
Profile [lbpr]
